PoliticalRepoPoliticalRepo

United States · Law · HR

H.R. 1503 (116th)

Orange Book Transparency Act of 2020

enactedUnited States· United States Congress· EN

Introduced

5 March 2019

Last action

—

Status

Became Public Law No: 116-290.

Sponsors

—

Subjects

Discovery layer

Source updated

28 May 2025

Official sourceDownload fileView documentsShare

Summary

Orange Book Transparency Act of 2019 This bill modifies requirements for the Food and Drug Administration (FDA) to list and publish drug patent and exclusivity information. Specifically, the FDA must include on its list certain patent information and must specify each drug exclusivity period that has not concluded. The holder of an approved drug application must notify the FDA when a listed patent is invalidated by a court or by the Patent Trial and Appeal Board. The FDA must remove invalidated patents from its list, subject to the 180-day drug exclusivity period.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

16 official files

Enrolled Bill (text)

View fileDownload file

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.